GSK Arm Says It Should Not Pay For All Uses Of Cancer Drug
A subsidiary of pharmaceutical giant GlaxoSmithKline focusing on cancer treatments told the Court of Appeal on Wednesday it should not pay all royalties to AstraZeneca on all sales of its ovarian...To view the full article, register now.
Already a subscriber? Click here to view full article